Shots: Photocure to receive $5M upfront within 6mos. after signing the agreement and $14M on the approval of the second indication in the US, China & EU with royalties on […]readmore
Tags : Agreement
Shots: Mundipharma to get exclusive rights to distribute, market and commercialize Tuznue in selected EU countries following marketing authorization, including France, Spain, Norway, Sweden, Denmark, Finland, Portugal, Switzerland and Austria […]readmore
Shots: GSK to get rights to develop and commercialize three additional inhaled therapies utilizing Liquidia’s PRINT technology and can acquire rights to pursue additional PRINT based inhalation therapies. Liquidia to […]readmore
Shots: Tilt initiates the collaboration with Merck KGaA & Pfizer to evaluate TILT-123 with avelumab in patients with solid tumors refractory to routine modalities TILT-123 will evaluate for solid tumors […]readmore
Shots: The agreement collaborates C4XD’s Taxonomy3 (target identification platform) with PhoreMost’s SITESEEKER (screening platform) to accelerate drug discovery initially focusing on Parkinson’s disease with expected profit sharing by both the […]readmore
Shots: Carna to receive $20M upfront, up to $450M as development & commercial milestones and royalties on sales. Gilead to get WW rights to develop and commercialize inhibitors against immuno-oncology […]readmore
Shots: GSK to receive $10.6M as termination fees and up to $7.907M as regulatory milestone for its VLA15. Valneva to regain complete control of its R&D assets including its Lyme […]readmore
Shots: Nurix to receive $45M upfront, up to $2.3B as milestones and royalties on sales, and will identify novel targets, utilizing its discovery platform & E3 ligases inducing degradation of […]readmore
Shots: Sanofi collaborated with Google to develop an Innovation lab, containing both scientific and commercial solutions with the aim to transform future drug & healthcare services with the involvement of […]readmore
Shots: BeiGene to receive $150M and regains WW rights for tislelizumab with their mutual termination of WW development & commercialization agreement with Celgene, following the pending acquisition of Celgene by […]readmore